Crispr Therapeutics Ag
Clinical trials sponsored by Crispr Therapeutics Ag, explained in plain language.
-
CRISPR Gene-Editing takes on blood cancers in new trial
Disease control Recruiting nowThis study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor T-cells that target and kill cancer cells. The trial involves …
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 26, 2026 10:31 UTC
-
CRISPR therapy targets stubborn high cholesterol in first human trial
Disease control Recruiting nowThis study is testing a new treatment called CTX310, which uses CRISPR gene editing to turn off a gene linked to high cholesterol and fats. It is for adults aged 18 to 75 whose lipid levels remain high despite standard treatments. The goal is to see if the therapy is safe and can…
Phase: PHASE1 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 19, 2026 11:48 UTC